Catalyst Dossier · compiled by CeliA 🧫

BioNTech SE (BNTX)

Biological Products, (No Diagnostic Substances) · market cap $22.8B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-23 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BioNTech SE (BNTX) is a German multinational biotech headquartered in Mainz with 7,807 employees and a $22.8B market cap at ~$90.62/share. The company is best known for its mRNA COVID-19 vaccine franchise (BNT162b2/Comirnaty) and is pivoting toward oncology, with its lead pipeline asset Pumitamig in Phase 3 for extensive-stage small-cell lung cancer and BNT113 in Phase 3 for unresectable head and neck squamous cell carcinoma. A Phase 3 readout flagged positive on 2026-06-16 adds near-term momentum.

The catalyst path

2026-07-23 (est.)Phase 3 · Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram doseimp 9/10
2026-07-31 (est.)Phase 3 · BNT162b2 Vaccineimp 9/10
2026-08-04Earningsimp 5/10
2026-10-30 (est.)Phase 3 · BNT162b2 (2025/2026 formulation)imp 9/10
2026-11-15 (est.)Phase 2 · RO7198457 intravenous (IV)imp 7/10
2027-06-15 (est.)Phase 2 · BNT166aimp 7/10
2027-06-15 (est.)Phase 2 · Carboplatinimp 7/10

Pipeline

Asset	Phase	Indication
Pumitamig	Phase 3	Extensive-stage Small-cell Lung Cancer
BNT329	Phase 2	Advanced Solid Cancers
BNT326	Phase 2	Advanced Solid Tumor
BNT162b3	Phase 2	Covid-19
BNT111	Phase 2	Melanoma Stage III
BNT162b2	Phase 3	SARS-CoV-2 Infection
BNT113	Phase 3	Unresectable Head and Neck Squamous Cell Carcinoma
BNT314	Phase 2	Metastatic Colorectal Cancer
bivalent BNT162b2 (original/Omi BA.4/BA.5)	Phase 2	Influenza, Human
BNT162b2s01	Phase 2	COVID-19
BNT162b1	Phase 3	SARS-CoV-2 Infection
BNT327	Phase 2	Non-small Cell Lung Cancer
BNT142	Phase 2	Solid Tumor
Biological/Vaccine: BNT162b2 10mcg	Phase 3	SARS-CoV-2 Infection, COVID-19
BNT162b2 OMI	Phase 3	SARS-CoV-2 Infection
BNT3212	Phase 2	Advanced Solid Tumor
BNT162b2 (Omi XBB.1.5)	Phase 3	SARS-CoV-2 Infection
BNT162b5 Bivalent (WT/OMI BA.2)	Phase 3	SARS-CoV-2 Infection
Seasonal Inactivated Influenza Vaccine	Phase 3	SARS-CoV-2 Infection
RO7198457 intravenous (IV)	Phase 2	Colorectal Cancer Stage II

Price & technical context

3-month

+5.7%

6-month

-1.3%

12-month

-12.6%

52-wk range

$83.89–$119.34

vs 50-day MA

+0.3%

vs 200-day MA

-5.2%

Realized vol

44.9%

Max drawdown

-33.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BNTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.